| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2143920 | Lung Cancer | 2007 | 4 Pages |
Abstract
SummaryBevacizumab is the first anti-angiogenic agent inhibiting vascular endothelial growth factor (VEGF) for treatment of patients suffering from cancer. Life-threatening hemoptysis is the most serious adverse effect of bevacizumab. The inhibition of VEGF is a possible mechanism involved in the destruction of normal lung tissue and subsequent hemoptysis. We report a case of bevacizumab-related hemoptysis and associated bronchoscopic findings that were successfully treated with rigid bronchoscopy and laser photocoagulation.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Young-Jae Cho, Septimiu D. Murgu, Henri G. Colt,